Ipsen Makes Another Major Investment of Up to $1.8 Billion in Rare Disease Pipeline

Ipsen, a renowned pharmaceutical company, has once again demonstrated its commitment to rare diseases with a significant investment. In an exciting development announced on April 22nd, Ipsen has entered into a research collaboration with Skyhawk Therapeutics to focus on rare neurological disorders. This partnership aims to explore the potential of RNA-targeted therapies in treating these challenging conditions. Ipsen's commitment extends to granting exclusive global rights to two candidate products, with potential milestone payments reaching as high as $1.8 billion.

Ipsen's collaboration with Skyhawk Therapeutics marks a notable step forward in the pursuit of innovative treatments for rare neurological disorders. Leveraging Skyhawk's unique platform, the partnership aims to develop RNA-targeted therapeutic candidates. The promising aspect of this collaboration is that Ipsen will have the opportunity to select two candidate products for further development and commercialization after the validation of the therapeutic candidates.

Under the terms of the agreement, Skyhawk Therapeutics stands to receive substantial financial support, including potential payments of up to $1.8 billion. These payments encompass development, regulatory, and commercial milestones, as well as upfront payments and potential tiered royalties. Ipsen's Senior Vice President and Head of Neuroscience and R&D, Steve Glyman, expressed enthusiasm about the collaboration, emphasizing the potential of modifying RNA expression in rare and debilitating neurological diseases.

Skyhawk Therapeutics, a clinical-stage biopharmaceutical company, specializes in the discovery and development of small molecules that modulate RNA. The field of RNA therapy has attracted significant attention, leading to collaborations between Skyhawk and major pharmaceutical companies such as Biogen, Takeda, Sanofi, and Merck. Skyhawk's innovative SkySTAR platform enables the discovery of small molecules that correct RNA splicing errors in the cell nucleus, restoring mRNA expression levels. This correction is of great significance, as RNA splicing errors can contribute to various neurological disorders, including neuroblastoma, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), frontotemporal dementia (FTD), and spinal muscular atrophy (SMA).

One of the most advanced candidates in Skyhawk's pipeline is SKY-0515, designed to treat Huntington's disease. SKY-0515 is a small molecule RNA splicing modulator that directly targets HTT RNA, and its oral administration allows it to penetrate the brain and peripheral tissues, offering potential benefits to patients. Currently, SKY-0515 is undergoing Phase 1 clinical trials.

Ipsen's dedication to oncology, rare diseases, and neuroscience has resulted in a diverse portfolio of drugs, including Increlex (mecasermin) for the treatment of severe primary insulin-like growth factor-1 deficiency in children and adolescents, Somatuline (lanreotide) for acromegaly and gigantism, and Sohonos (palovarotene) for progressive fibrodysplasia ossificans.

Over the years, Ipsen has expanded its footprint in the rare disease field, with notable acquisitions such as Albireo Pharma in January last year, strengthening its rare disease portfolio. Ipsen's latest collaboration with Skyhawk Therapeutics reinforces its commitment to addressing unmet medical needs in rare neurological disorders.

Ipsen's collaboration with Skyhawk Therapeutics represents a significant investment in the development of RNA-targeted therapies for rare neurological disorders. With the potential for milestone payments reaching up to $1.8 billion, Ipsen's commitment underscores its dedication to advancing innovative treatments in the field. The partnership holds the promise of addressing the challenges posed by rare diseases and improving the lives of patients affected by these conditions.